Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

BACKGROUND. Immune‐related adverse events (irAEs) have emerged as a serious clinical issue in the use of immune checkpoint inhibitors (ICIs). Risk factors for irAEs remain controversial. Therefore, we studied sex differences in irAEs in patients treated with anti‐programmed cell death protein 1 (PD‐...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Duma, Narjust, Abdel‐Ghani, Azzouqa, Yadav, Siddhartha, Hoversten, Katherine P., Reed, Clay T., Sitek, Andrea N., Enninga, Elizabeth Ann L., Paludo, Jonas, Aguilera, Jesus Vera, Leventakos, Konstantinos, Lou, Yanyan, Kottschade, Lisa A., Dong, Haidong, Mansfield, Aaron S., Manochakian, Rami, Adjei, Alex A., Dronca, Roxana S.
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2019
Sujets:
Immuno‐Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853107/
https://ncbi.nlm.nih.gov/pubmed/31036771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0094
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires